Literature DB >> 27141342

CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.

Julie Leignadier1, Stephanie Favre2, Sanjiv A Luther2, Immanuel F Luescher1.   

Abstract

Cytotoxic T lymphocytes (CTL) from CD8β-deficient mice have powerful FasL-mediated cytotoxicity and IFNγ responses, but ablated Ca2+ and NFAT signaling, which can be restored by transduction with CD8β. Upon infection with lymphocytic choriomeningitis virus (LCMV), these cells yielded GP33-specific CTL (CD8βR) that exhibited high FasL/Fas-mediated cytotoxicity, IFNγ CXCL9 and 10 chemokine responses. Transfer of these cells in B16-GP33 tumor bearing mice resulted in (i) massive T cell tumor infiltration, (ii) strong reduction of myeloid-derived suppressor cells (MDSCs), regulatory T cells (Treg) and IL-17-expressing T helper cells, (iii) maturation of tumor-associated antigen-presenting cells and (iv) production of endogenous, B16 melanoma-specific CTL that eradicated the tumor long after the transferred CD8βR CTL perished. Our study demonstrates that the synergistic combination of strong Fas/FasL mediated cytotoxicity, IFNγ and CXCL9 and 10 responses endows adoptively transferred CTL to reprogram the tumor environment and to thus enable the generation of endogenous, tumoricidal immunity.

Entities:  

Keywords:  B16 melanoma; CD8+ T cell; FasL; IFNγ; chemokines

Year:  2015        PMID: 27141342      PMCID: PMC4839323          DOI: 10.1080/2162402X.2015.1086861

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  53 in total

Review 1.  Cellular constituents of immune escape within the tumor microenvironment.

Authors:  Sid P Kerkar; Nicholas P Restifo
Journal:  Cancer Res       Date:  2012-06-21       Impact factor: 12.701

2.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  The critical role of protein kinase C-theta in Fas/Fas ligand-mediated apoptosis.

Authors:  Santhakumar Manicassamy; Zuoming Sun
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Authors:  J P Medema; J de Jong; L T Peltenburg; E M Verdegaal; A Gorter; S A Bres; K L Franken; M Hahne; J P Albar; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

5.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

6.  CD8beta knockout mice mount normal anti-viral CD8+ T cell responses--but why?

Authors:  Georgi S Angelov; Philippe Guillaume; Immanuel F Luescher
Journal:  Int Immunol       Date:  2008-12-15       Impact factor: 4.823

7.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Authors:  Sid P Kerkar; Anthony J Leonardi; Nicolas van Panhuys; Ling Zhang; Zhiya Yu; Joseph G Crompton; Jenny H Pan; Douglas C Palmer; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

8.  Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Eric Tran; Zhiya Yu; Richard A Morgan; Nicholas P Restifo; Steven A Rosenberg
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

9.  IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas.

Authors:  Michel Buferne; Lionel Chasson; Magali Grange; Amandine Mas; Fanny Arnoux; Mélanie Bertuzzi; Philippe Naquet; Lee Leserman; Anne-Marie Schmitt-Verhulst; Nathalie Auphan-Anezin
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

10.  Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice.

Authors:  Keiji Hayata; Makoto Iwahashi; Toshiyasu Ojima; Masahiro Katsuda; Takeshi Iida; Mikihito Nakamori; Kentaro Ueda; Masaki Nakamura; Motoki Miyazawa; Toshiaki Tsuji; Hiroki Yamaue
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

View more
  6 in total

1.  Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer.

Authors:  Tao Jiang; Xiao Chen; Wei Zhou; Guoxin Fan; Peilin Zhao; Shengxiang Ren; Caicun Zhou; Jun Zhang
Journal:  Transl Oncol       Date:  2017-01-25       Impact factor: 4.243

2.  'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.

Authors:  Debottam Sinha; Sriganesh Srihari; Kirrliee Beckett; Laetitia Le Texier; Matthew Solomon; Archana Panikkar; George R Ambalathingal; Lea Lekieffre; Pauline Crooks; Sweera Rehan; Michelle A Neller; Corey Smith; Rajiv Khanna
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

Review 3.  Targeting regulatory T cells for immunotherapy in melanoma.

Authors:  Lili Huang; Yeye Guo; Shujing Liu; Huaishan Wang; Jinjin Zhu; Lingling Ou; Xiaowei Xu
Journal:  Mol Biomed       Date:  2021-04-19

4.  Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.

Authors:  Yuan Yuan; Zheng Zhu; Ying Lan; Saili Duan; Ziqing Zhu; Xi Zhang; Guoyin Li; Hui Qu; Yanhui Feng; Hui Cai; Zewen Song
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

Review 5.  From pathogenesis to clinical application: insights into exosomes as transfer vectors in cancer.

Authors:  Wenting Xu; Zhen Yang; Nonghua Lu
Journal:  J Exp Clin Cancer Res       Date:  2016-09-29

6.  Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis.

Authors:  Lili Huang; Hong Chen; Yu Xu; Jianhua Chen; Zhuqing Liu; Qing Xu
Journal:  Cancer Med       Date:  2020-09-15       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.